Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadjuvant strategies have been developed to treat micrometastatic disease and increase the probability of a complete resection. The optimal induction strategy has not yet been defined, however, with arguments favoring either preoperative chemotherapy or CRT. In this article, the data supporting the use of neoadjuvant CRT and the randomized literature comparing the two approaches will be reviewed. The article will conclude with summary comparisons of these induction paradigms.

Original languageEnglish (US)
Article number281
JournalFrontiers in Oncology
Issue numberDEC
StatePublished - Dec 4 2017


  • Combined modality therapy
  • Lung cancer
  • Neoadjuvant therapy
  • Radiation therapy
  • Stage III non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this